Juan  Vera net worth and biography

Juan Vera Biography and Net Worth

Director of AlloVir
Dr. Vera is an Associate Professor at Baylor College of Medicine.
Dr. Juan Vera has more than 15 years of experience performing research in the field of adoptive T cell therapy and has made several contributions in the field, specifically in the areas of genetic engineering T cells manufacture process optimization. He has extensive expertise developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability.

In collaboration with Wilson Wolf Manufacturing, Dr. Vera has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. He is a Co-Investigator on a number of clinical trials for T cell therapy in both infectious disease and cancer. His recent focus is on developing strategies to enhance the T cell function by protecting tumor-targeted T cells from the immunosuppressive effects of the tumor microenvironment in order to enhance in vivo persistence and function.

Dr. Vera is senior or co-author on more than 30 publications and a named inventor on 13 published patents. He is based at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston where he holds the title of Associate Professor in the Dept. of Medicine. Dr. Vera received his Medical Degree from the University El Bosque in Bogota, Colombia and completed his postgraduate training in theCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital.

What is Juan Vera's net worth?

The estimated net worth of Juan Vera is at least $24.90 million as of March 16th, 2021. Dr. Vera owns 2,564,487 shares of AlloVir stock worth more than $24,901,169 as of February 10th. This net worth approximation does not reflect any other investments that Dr. Vera may own. Learn More about Juan Vera's net worth.

How do I contact Juan Vera?

The corporate mailing address for Dr. Vera and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at ir@allovir.com. Learn More on Juan Vera's contact information.

Has Juan Vera been buying or selling shares of AlloVir?

Juan Vera has not been actively trading shares of AlloVir within the last three months. Most recently, Juan Vera sold 695 shares of the business's stock in a transaction on Wednesday, March 3rd. The shares were sold at an average price of $881.36, for a transaction totalling $612,545.20. Following the completion of the sale, the director now directly owns 104,008 shares of the company's stock, valued at $91,668,490.88. Learn More on Juan Vera's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, insiders at the sold shares 46 times. They sold a total of 4,971 shares worth more than $82,278.96. The most recent insider tranaction occured on January, 23rd when General Counsel Edward Miller sold 52 shares worth more than $494.00. Insiders at AlloVir own 32.1% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 1/23/2025.

Juan Vera Insider Trading History at AlloVir

See Full Table

Juan Vera Buying and Selling Activity at AlloVir

This chart shows Juan Vera's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total Insider BuyingTotal Insider Selling

AlloVir Company Overview

AlloVir logo
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Read More

Today's Range

Now: $9.71
Low: $9.61
High: $10.16

50 Day Range

MA: $10.29
Low: $8.77
High: $12.22

2 Week Range

Now: $9.71
Low: $7.96
High: $24.15

Volume

20,504 shs

Average Volume

37,427 shs

Market Capitalization

$48.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65